Endometrium adenocarcinoma
MONDO:0005461An adenocarcinoma arising from the uterine body cavity. This is the most frequent malignant tumor affecting the uterine body, and is linked to estrogen therapy. Most patients present with uterine bleeding and are over age 40 at the time of diagnosis. The prognosis depends on the stage of the tumor, the depth of the uterine wall invasion, and the histologic subtype. Endometrioid adenocarcinoma is the most frequently seen morphologic variant of endometrial adenocarcinoma.
Also known as: endometrioid carcinoma of endometrium, adenocarcinoma of endometrium, adenocarcinoma of the endometrium, adenocarcinoma, endometrial, malignant, endometrial adenocarcinoma, endometrioid adenoma or carcinoma NOS (morphologic abnormality), endometrioid adenomas and carcinomas (morphologic abnormality), endometrium adenocarcinoma
2964 clinical trials for this condition and its sub-types, 30 tagged with Endometrium adenocarcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Endometrium adenocarcinoma
-
Ovarian endometrioid adenocarcinoma 78 trials
1 sub-type
-
Endometrial clear cell adenocarcinoma 21 trials
-
Endometrial mixed adenocarcinoma 10 trials
-
Endometrial mucinous adenocarcinoma 2 trials
-
Immunotherapy duo shows promise for Tough-to-Treat uterine cancer
Disease control Recruiting nowThis phase II trial is testing whether combining two immunotherapy drugs, nivolumab and ipilimumab, works better than nivolumab alone for women with recurrent endometrial cancer that has a specific DNA repair defect (dMMR). About 81 participants will receive either the combinatio…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
New drug targets Hard-to-Treat cancers with genetic weakness
Disease control Recruiting nowThis study tests a new drug, TER-2013, in people with advanced solid tumors (like breast, ovarian, or lung cancer) that have specific genetic changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and can shrink tumors. About 205 participants will receive th…
Phase 1/2 • Sponsor: Terremoto Biosciences Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New biologic drug DBC-664 takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing an experimental biologic drug, DBC-664, in adults with advanced solid tumors such as ovarian, lung, and stomach cancers that have spread or come back. The study has two parts: first, finding a safe dose, and then expanding to see how well the dru…
Phase 1 • Sponsor: Duboce Biopharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New drug combo aims to shrink endometrial tumors
Disease control Recruiting nowThis Phase 2 trial tests an experimental drug called ACR-368, alone or with a low dose of gemcitabine, in 350 people with high-grade endometrial cancer. A special test (OncoSignature) helps decide which treatment arm a participant joins. The main goal is to see if the drug shrink…
Phase 2 • Sponsor: Acrivon Therapeutics • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New drug aimed at folate receptor shows promise for tough endometrial cancer
Disease control Recruiting nowThis phase 2 trial tests a drug called mirvetuximab soravtansine in 50 women with a specific type of endometrial cancer that has come back or won't go away. The drug targets a protein called folate receptor alpha, which is often found on these cancer cells. Researchers want to se…
Phase 2 • Sponsor: Alessandro Santin • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Virus therapy takes on cervical and endometrial cancer
Disease control Recruiting nowThis study tests a modified virus (KD01) that targets and kills cancer cells, given alone or with an immunotherapy drug (AK104). It includes 97 women with cervical or endometrial cancer, some of whom have not responded to standard treatments. The goal is to see if the virus is sa…
Phase 1 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Can a simple blood test predict leukemia risk after cancer therapy?
Knowledge-focused Recruiting nowThis study investigates clonal hematopoiesis (CH) — small mutations in blood cells that can arise naturally or after cancer treatment — in adults receiving chemotherapy or radiation for solid tumors like breast, lung, or colorectal cancer. Researchers will collect blood, saliva, …
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Blood test aims to spot hidden cancer cells in 9 tumor types
Knowledge-focused Recruiting nowThis study is looking for certain cells in the blood of people with 9 types of advanced cancers that have spread. Researchers will take one blood sample from each of 450 participants before they start a new treatment. They will use two different lab methods to see if they can fin…
Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Ultrasound-MRI fusion could sharpen cancer radiation targeting
Knowledge-focused Recruiting nowThis early study at Duke University is testing whether combining transrectal ultrasound (TRUS) images with MRI scans can help doctors guide needles more accurately during brachytherapy for uterine cancer. The researchers will enroll 17 adults with uterine or cervical cancer who a…
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC